University Medical Center Utrecht — Sponsor Intelligence | 12 EU Trials

Filter these 12 trials by condition, phase, country and more.

Open in Search →

12 Registered trials

4 Recruiting

5 Completed trials

14 Countries active

44 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase III: 2 Phase II/III: 1 Phase II: 4 Phase IV: 5

Oversight events:

2 serious breaches 1 corrective measure across 3 trials

View oversight register →

100%

5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Antisynthetase syndrome 2 Dermatomyositis 2 Infertility tests normal 1 Schizophrenia 1 Infertility female 1 Infertility 1 Respiratory tract infection 1 Insulin-requiring type 2 diabetes mellitus 1

Top IMPs

DIROCAFTOR 2 FILGOTINIB 2 NESOLICAFTOR 2 POSENACAFTOR 2 ESKETAMINE HYDROCHLORIDE 1 INSULIN GLARGINE 1 NITRIC OXIDE 1 PROGESTERONE, MICRONISED 1 SODIUM CHLORIDE SOLUTION 0.9% 1 TECOVIRIMAT 1 VOXVOGANAN 1 ZANUBRUTINIB 1

All trials

12 total

A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/… Not authorised

2022-500410-26-00 Phase III 9 countries DIROCAFTOR; NESOLICAFTOR; POSENACAFTOR
A randomised, controlled trial to investigate the effect of a four/six week intensified pharmacological treatment for schizophrenia, major d… Not authorised

2022-502185-24-00 Phase III 4 countries ESKETAMINE HYDROCHLORIDE
Drug Rediscovery for rare Immune Mediated Inflammatory Diseases (DRIMID) Not authorised

2022-502968-20-01 Phase II 1 country FILGOTINIB
Stem cell transplantation in diffuse cutaneous systemic sclerosis: upfront therapy or rescue therapy after failure of immunosuppressants Recruiting

2023-505877-34-00 Phase IV 3 countries
Drug Rediscovery for rare Immune Mediated Inflammatory Diseases (DRIMID) Recruiting

2022-502968-20-02 Phase II 1 country FILGOTINIB
Multicenter, open-label, phase II study in patients with immunoglobulin M monoclonal gammopathy of unknown significance and Myelin Associate… Recruiting

2023-505933-29-00 Phase II 1 country ZANUBRUTINIB
Staphylococcus aureus Network Adaptive Platform trial (SNAP) Recruiting

2023-503582-35-00 Phase IV 4 countries
Clinical trial for the treatment of COVID-19 and COVID-like illness in primary care Ended

2022-501707-27-01 Phase II/III 6 countries NITRIC OXIDE; SODIUM CHLORIDE SOLUTION 0.9%; VOXVOGANAN
Does progesterone luteal phase support increase live birth rates in couples undergoing intra-uterine insemination with Mild Ovarian HyperSti… Ended

2022-501534-33-00 Phase IV 1 country PROGESTERONE, MICRONISED
European randomised clinical trial on mPOX Infection (EPOXI) Ended

2022-501979-10-00 Phase IV 8 countries TECOVIRIMAT
A Phase IIb, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Dirocaftor/Po… Ended

2022-500410-26-01 Phase II 9 countries DIROCAFTOR; NESOLICAFTOR; POSENACAFTOR
The RADIAL study: A clinical trial to learn more about the benefits and the acceptability of trials that include technology to centre the tr… Ended

2022-500449-26-00 Phase IV 5 countries INSULIN GLARGINE

Showing 1–12 of 12 trials

← All sponsors A–Z